Prediction: These 2 Stocks Could Double In the Next Year
The next 12 months could be dicey for the economy and the stock market, especially as the U.S. Federal Reserve recently predicted a recession could come by year-end. But even in this environment, some equities should perform just fine -- or even better.
Let's look at two examples: CRISPR Therapeutics (NASDAQ: CRSP) and Axsome Therapeutics (NASDAQ: AXSM). These two biotechs have important catalysts that could lead to outsized gains in the near term and, even more importantly, over the long run.
CRISPR Therapeutics is a gene-editing-focused biotech with no product on the market. That could be about to change. The company has submitted regulatory applications for its leading candidate, exa-cel, in the U.S. and Europe. Exa-cel is a potential therapy for a pair of blood-related illnesses: transfusion-dependent beta-thalassemia (TDT) and sickle cell disease (SCD).
Source Fool.com
Axsome Therapeutics Inc Aktie
Wenige Einschätzungen bei Axsome Therapeutics Inc lassen noch kein klares Bild zu.
Für Axsome Therapeutics Inc ergibt sich mit einem Kursziel von 100 € eine mögliche Steigerung von über 20% gegenüber 82.24 €.
